The clinical significance of patients’ sex in chronic lymphocytic leukemia

Daniel Catovsky,1 Rachel Wade,2 and Monica Else1

1Haemato-Oncology Research Unit, Division of Molecular Pathology, The Institute of Cancer Research, London; and 2Clinical Trial Service Unit, Oxford, UK.

©2014 Ferrata Storti Foundation. This is an open-access paper. doi:10.3324/haematol.2013.101378
Manuscript received on November 19, 2013. Manuscript accepted on March 18, 2014.
Correspondence: daniel.catovsky@icr.ac.uk
SUPPLEMENTARY FIGURE 1: Overall survival by sex in each individual randomized trial

1A: CLL1 (363 patients)

1B: CLL2 (286 patients)
Patients at risk:
Females | 97 | 78 | 61 | 42 | 29 | 17
Males   | 298| 223| 159| 88 | 41 | 22

1C: CLL3 (395 patients)

Patients at risk:
Females | 204| 177| 145| 111| 82 | 32
Males   | 573| 472| 364| 269| 163| 58

1D: LRF CLL4 (777 patients)
SUPPLEMENTARY FIGURE 2: Overall survival by sex within sub-groups

2A: Overall survival by sex within each disease stage (all randomized trials)

2B: Overall survival by sex within each age group (all randomized trials)
SUPPLEMENTARY FIGURE 3: Overall survival with response to treatment, and progression-free survival, by sex

3A: Overall survival by sex and response to first-line treatment (all randomized trials)

3B: Progression-free survival by sex (LRF CLL4 trial only)